NAT2Genotype | Sporadic-CRC | IBD benign | IBD dysplasia/cancer | Controls | Phenotype | ||||
---|---|---|---|---|---|---|---|---|---|
 | No. | % | No. | % | No. | % | No. | % |  |
NAT2*5B/*6A | 26 | 21.3 | 85 | 23.22 | 5 | 33.33 | 54 | 24.3 | Slow |
NAT2*4/*5B | 22 | 18 | 72 | 19.67 | 1 | 6.66 | 39 | 17.5 | Intermediate |
NAT2*5B/*5B | 17 | 13.9 | 54 | 14.75 | 3 | 20 | 32 | 14.4 | Slow |
NAT2*4/*6A | 24 | 19.7 | 48 | 13.11 | 4 | 26.66 | 30 | 13.5 | Intermediate |
NAT2*6A/*6A | 16 | 13.2 | 20 | 5.46 | Â | Â | 21 | 9.45 | Slow |
NAT2*4/*4 | 3 | 2.45 | 26 | 7.1 | Â | Â | 16 | 7.2 | Rapid |
NAT2*6A/*7B | 3 | 2.45 | 6 | 1.63 | Â | Â | 3 | 1.36 | Slow |
NAT2*5B/*7B | 2 | 1.63 | 8 | 2.18 | Â | Â | 5 | 2.25 | Slow |
NAT2*5B/*5C | 2 | 1.63 | 2 | 0.54 | Â | Â | 4 | 1.8 | Slow |
NAT2*5A/*6A | 0 | 0 | 2 | 0.54 | Â | Â | 2 | 0.9 | Slow |
NAT2*5B/*13 | 0 | 0 | 5 | 1.36 | 1 | 6.66 | 2 | 0.9 | Intermediate |
NAT2*4/*5A | 0 | 0 | 5 | 1.36 | Â | Â | 2 | 0.9 | Intermediate |
NAT2*4/*7B | 2 | 1.63 | 5 | 1.36 | 1 | 6.66 | 2 | 0.9 | Intermediate |
NAT2*5C/*6A | 0 | 0 | 3 | 0.819 | Â | Â | 2 | 0.9 | Slow |
NAT2*5A/*5B | 1 | 0.81 | 8 | 2.18 | Â | Â | 1 | 0.45 | Slow |
NAT2*5A/*5C | 0 | 0 | 2 | 0.54 | Â | Â | 1 | 0.45 | Slow |
NAT2*5B/*12A | 1 | 0.81 | 0 | 0 | Â | Â | 1 | 0.45 | Intermediate |
NAT2*5C/*5C | 0 | 0 | 1 | 0.27 | Â | Â | 1 | 0.45 | Slow |
NAT2*4/*12A | 0 | 0 | 0 | 0 | Â | Â | 1 | 0.45 | Rapid |
NAT2*4/*5C | 1 | 0.81 | 7 | 1.91 | Â | Â | 1 | 0.45 | Intermediate |
NAT2*6A/*12A | 0 | 0 | 0 | 0 | Â | Â | 1 | 0.45 | Intermediate |
NAT2*6A/*13 | 1 | 0.81 | 1 | 0.27 | Â | Â | 1 | 0.45 | Intermediate |
NAT2*4/*13 | 0 | 0 | 2 | 0.54 | Â | Â | 0 | 0 | Rapid |
NAT2*5A/*13 | 0 | 0 | 1 | 0.27 | Â | Â | 0 | 0 | Intermediate |
NAT2*5A/*5A | 1 | 0.81 | 1 | 0.27 | Â | Â | 0 | 0 | Slow |
NAT2*5C/*7B | 0 | 0 | 2 | 0.54 | Â | Â | 0 | 0 | Slow |
Total | 122 | Â | 366 | Â | 15 | Â | 222 | Â | Â |